Tyrosine Kinases in the Regulation of Platelet Signaling: Quentin Hill Shares a PhD Opportunity
Quentin Hill, Consultant Haematologist at Leeds Teaching Hospitals NHS Trust, reposted from The Platelet Society on LinkedIn:
”And they keep coming!
Platelet biology, a fascinating topic for a PhD.”
Quoting The Platelet Society‘s post:
”PhD project opportunity!
Exciting 4-year PhD studentship available as part of the SWBio DTP PhD programme at the University of Bristol, using Proteolysis-Targeting Chimeras (PROTACs) and molecular modeling to explore how tyrosine kinases regulate platelet signaling and function.
You will gain hands-on experience in targeted protein degradation, computational modeling, and platelet biology, and will be jointly supervised by Professor Ingeborg Hers, Dr Robin Corey and Prof Varinder Aggarwal in a vibrant interdisciplinary training environment.
Project title: Targeted Protein Degradation as a Cutting-Edge Tool to Study Tyrosine Kinases in Platelet Signaling and Function (Project ID 267)
Apply by the 3rd December 2025.
Check out further details.”
Stay updated with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial